



Syngene

Putting Science to Work

Discovery Services

Innovate

Integrate

Customize

Accelerate


Putting Science to Work



- **27 years of solving complex innovation and ROI challenges for our clients**
- Syngene **has a track record of success** spanning over 2 decades
- 400+ active clients last FY
- 413 patent assignments by clients recognizing Syngene
- Over 15+ regulatory and ~250 client audits in the last 3 years



- **Our scale, world-class technology and the smartest people** help drive your research programs forward
- ~1.9 Mn sq. ft. world-class R&D and Manufacturing infrastructure
- Strong management team with ~300 person-years of global biopharma experience
- 4700+ qualified scientists including ~500 PhDs
- Ongoing \$200Mn investment program



- **We offer innovative partnership models** to drive business outcomes
- FTE, FFS, risk-reward
- Up to 25% efficiency gain/FTE through dedicated R&D centers - BMS, Baxter, Amgen



Integrated Drug Discovery

Across multiple therapeutic areas and modalities to drive innovation and speed

Therapeutic Areas

- Oncology
- Immunology
- Neuroscience
- Infectious diseases
- Cardiovascular and metabolism
- Inflammation
- Rare/orphan diseases

Modalities

- Small molecules
- Peptides
- Oligonucleotides
- Antibodies
- Antibody drug conjugates
- PROTACs
- CAR-Ts

Drug discovery at a global scale

1600

scientists, with
95%+ Ms/Ph.D.

600,000

sq. ft. of
lab space

200+

global
clients

Efficiency through co-localization of team members and capabilities

- IDD programs for 8 clients over 6 therapeutic areas
- Syngene-Synvent for therapeutic discovery on behalf of clients
- High rate of repeat business and return-clients



Realize Your Next







Drug candidate through our Chemistry, Biology, Safety/Tox and Computational and Data Sciences

- 95% on time delivery rate for known target compounds, >90% for unknown targets
- 25,000 reagents and 8,000 unique scaffolds in stock
- LCMS lab with ability to perform 96000 analyses/year and access to NMR lab to run 25000 samples/ year
- High-throughput mass based preparative HPLC lab for purifications with current capacity of 30000 compounds/year
- Completed ~40 PROTACs libraries (>98% success rate)
- 5000+ compounds in HT ADME assays / year
- 2500+ rodent (n=3) PK studies / year
- ADME studies turnaround in ~10 calendar days with >95% TAT adherence
- Computational and Data Sciences support across multiple stages of the discovery paradigm
- Effective use of CADD, cheminformatics and AI for multiparametric optimization




Our Discovery Toolbox

We have the capabilities to apply the most appropriate modality for target validation and therapeutic discovery



Our End-to-End Discovery Platform

Our end-to-end platform allows us to offer integrated as well as standalone services across the discovery continuum



We deliver our services (both Integrated & Functional) via a range of proven collaboration models



Dedicated R&D Labs




FTE




FFS

Discovery Chemistry at Syngene

Discovery chemistry at Syngene is delivered by 900+ highly qualified scientists, backed by strong analytical chemistry support, robust IT infrastructure and ELN, as well as efficient data and compound management



Integrated & collaborative drug discovery
Seamless co-ordination between Chemistry, Biology, DMPK and animal studies



Analytical facilities supported by a team of 80 people
Strong IT support for ELN, data and compound management

Discovery Biology at Syngene

The Discovery Biology team supports drug discovery across multi-modal platforms including small and large molecules as well as cell and gene therapy, across multiple therapy areas. Our diverse team of scientists solve complex biological problems in an integrated fashion, embracing scientific excellence, operational efficiency and commercial competitiveness.



650+
scientists



110,000
sq. ft lab space
State of the art
infrastructure



Protein
Sciences



Cell
Engineering



Antibody Discovery
and engineering



Genomics and
translational



Assay Biology
& Screening



ADME DMPK



In Vivo
Pharmacology

Syngene Safety Assessment Services

Full range of *in vivo* and *in vitro* toxicology services for comprehensive non-clinical development of drugs

Exploratory studies	GLP studies	Phase I	Phase II	Phase III	Specialty studies
Pharmacokinetics	Analytical and bioanalytical studies to support safety tox program	Repeat dose studies & Genetic toxicology	Sub-chronic toxicity study		<i>In silico</i>
(MTD/Dose Escalation/Short-term repeat dose toxicology)	Repeat Dose Toxicology (2 Species)				Reproductive Toxicology (Male fertility/ Pre and Postnatal development)
Genotoxicity screening (<i>in vitro</i>)	Genotoxicity (<i>In vitro/ In vivo</i>)	Repeat dose studies & Genetic toxicology	Chronic Toxicology & Carcinogenicity		
Safety Pharmacology: CNS, Respiratory, CV	Toxicokinetics				Chronic Toxicology & Carcinogenicity
	Core Battery Safety Pharmacology				
	Reproductive (Seg I-III) & Juvenile Toxicology				<ul style="list-style-type: none"> Impurity Qualification Medical Device Testing - ISO10993 Dermal Tox - Rat & Rabbit Local tolerance/ irritation - Rat & Rabbit GPMT/LLNA Intravenous infusion - Rat Phototoxicity

Computational and Data Sciences Capabilities

Syngene's Computational and Data Sciences capabilities enable informed decisions at all stages of the drug discovery continuum



Target
Identification and
Validation



Hit
Identification




Hit to
Lead



Lead
Optimization



Candidate
Selection





Syngene
Putting Science to Work

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors. Syngene's more than 4700 scientists offer both skills and the capacity to deliver great science, robust data management and IP security and quality manufacturing at speed to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter and Bristol-Myers Squibb, as well as 2 Mn sq. ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK and Merck KGaA.

For more details, visit www.syngeneintl.com or write to us at bdc@syngeneintl.com

© 2022 Syngene International Limited, All Rights Reserved.

Stay Connected

